报价延迟最少15分钟:2025/12/20 04:03 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.17 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.22/-0.46
|
|
企业价值
90.80M
|
| 资产负债 |
|
每股账面净值
0.24
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
--
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States. |
